Professional Documents
Culture Documents
ENVORINMENT OF
BUISNESS
TERM PAPER
ON
SUBMITTED TO :
DR. MEGHA CHANDIOK
ON
4.11.2008
BY :
GROUP 3
PRANAY SHARMA (36/08)
ANJU BALA AHUJA (48/08)
INDERDEEP KAUR (56/08)
NIPUN TRIKHA (58/08)
ANKITDEEP SINGH (82/08)
ABHISKEHK CHANANA (138/08)
pg. 1
TABLE OF CONTENTS pg no
1. INTRODUCTION 3
2. INTRODUCTION TO TRIPs 4
3. FEATURES 6
3.1 Non-discrimination
3.2 Duration of iprs
3.3 Scope of iprs
3.4 Licensing
3.5 Transition period for ldcs
3.6 Enforcement mechanism
4. NECESSITY 8
4.1 Protection
4.2 New situations and problems
4.3 US interest
4.4 Benefits to developed nations
4.5 Cost of r&d
5. DIFFERENT IPRs 9
5.1 Copyrights and Related rights
5.2 Trademarks
5.3 Geographical indications
5.4 Industrial designs
5.5 Patents
Issues and doha rounds of talks on public health
5.6 Layout-designs of integrated circuits
5.7 Protection of undisclosed information
5.8 Control of anti-competitive practices in
contractual licenses
6. IMPACT OR TRIPs ON INDIAN SECTORS 13
6.1 Software sector
6.2 Pharmaceutical sector
I. Indian patent law 1970
II. TRIPS and public health
6.3 Agricultural sector
6.4 Traditional knowledge and bio diversity
I. Reasons
II. Negotiations
7. CONCLUSION 19
8. ENFORCEMENT 19
9. RECENT DISPUTES 20
10.CRITICISMS 21
11. BIBLIOGRAPHY &WEBSITES 22
pg. 2
INTRODUCTION
Ideas and knowledge are an increasingly important part of trade. Most of the
value of new medicines and other high technology products lies in the
amount of invention, innovation, research, design and testing involved.
Films, music recordings, books, computer software and on-line services are
bought and sold because of the information and creativity they contain, not
usually because of the plastic, metal or paper used to make them. Many
products that used to be traded as low-technology goods or commodities
now contain a higher proportion of invention and design in their value — for
example brand named clothing or new varieties of plants.
Creators can be given the right to prevent others from using their inventions,
designs or other creations — and to use that right to negotiate payment in
return for others using them. These are “intellectual property rights”. They
take a number of forms. For example books, paintings and films come under
copyright; inventions can be patented; brandnames and product logos can be
registered as trademarks; and so on. Governments and parliaments have
given creators these rights as an incentive to produce ideas that will benefit
society as a whole.
The concept of intellectual property seeks to divorce the idea itself, which is
treated as freely shareable, from the expression of the idea, the design or
process, which becomes property. As the design or process becomes
increasingly abstract, it becomes harder to distinguish it from the idea
behind it. The difficulty in making this distinction is a serious dilemma that
patent offices worldwide are having to increasingly grapple with, a problem
that is becoming more serious as marketable products become more abstract
in an information age.
pg. 3
INTRODUCTION TO TRIPs
Background
The extent of protection and enforcement of these rights varied widely
around the world; and as intellectual property became more important in
trade, these differences became a source of tension in international economic
relations. Certain agreements on IP rights already existed before the WTO
was created:
• the Paris Convention for the Protection of Industrial Property
1883(patents, industrial designs, etc)
• the Berne Convention for the Protection of Literary and Artistic
Works 1886 (copyright).
TRIPS
In Uraguay rounds (1987) TRIPS were included for the first time in WTO
with US being the prime mover. Brazil and India were leading the
opposition from the side of developing nations. Developed nations argued
that entrepreneurship and innovation could never be encouraged without
proper protection of intellectual property rights, while Developing nations
contended that the rights of the patent-holder or inventor would need to be
circumscribed by his/ her obligations to the rest of society and the world at
large.
pg. 4
intellectual property protection encourages creation and invention, especially
when the period of protection expires and the creations and inventions enter
the public domain. Governments are allowed to reduce any short term costs
through various exceptions, for example to tackle public health problems.
And, when there are trade disputes over intellectual property rights, the
WTO’s dispute settlement system is now available.
Basic principles:
• national treatment: treating one’s own nationals and foreigners
equally),
• most-favoured-nation treatment (equal treatment for nationals of all
trading partners in the WTO
• Balanced protection : intellectual property protection should
contribute to technical innovation and the transfer of technology.
Both producers and users should benefit, and economic and social
welfare should be enhanced.
pg. 5
The main features of the Agreement are:
1. Nondiscrimination. It signifies that Member states must not favor the
intellectual property rights of their own citizens against the intellectual
property rights of citizens of other GATT members, and they must not favor
the rights of citizens of one member country over those of another.
pg. 6
7. Licensing: This is an area where international disputes are common.
TRIPS has failed to resolve the sources of conflict because it allows nations
to grant compulsory licenses for "adequate remuneration" after considering
each case "on its individual merits" and after attempting to negotiate
"reasonable commercial terms" with holders of intellectual property rights.
TRIPS specifies that compulsory licenses must be nonexclusive and of
limited duration.
pg. 7
NECESSITY FOR TRIP’s
There are several reasons for the emergence of TRIPS. They are-
pg. 8
DIFFERENT IPRs
TRIPS agreement includes the following intellectual property rights (IPRs):
5.2 Trademarks
1. The basic rule contained in Article 15 is that any sign, or any combination
of signs, capable of distinguishing the goods and services of one undertaking
from those of other undertakings, must be eligible for registration as a
trademark, provided that it is visually perceptible.
pg. 9
3. The owner of a registered trademark must be granted the exclusive right
to prevent all third parties not having the owner's consent from using in the
course of trade identical or similar signs for goods or services.
Wine and spirits makers are particularly concerned about the use of place-
names to identify products, and the TRIPS Agreement contains special
provisions for these products. But the issue is also important for other types
of goods.
5.5 Patents
Patents must be available for any inventions, whether products or processes,
in all fields of technology without discrimination, subject to the normal tests
of novelty, inventiveness and industrial applicability. They are issued for a
period of 20 years.
pg. 10
The exclusive rights includes right to make, use, sell. Imported products
enjoy same rights in any other country.
Process patents will also apply to products directly received from the
process. An applicant for a patent shall disclose the invention in a manner
sufficiently clear and complete for the invention to be carried out by a
person skilled in the art.
EXCEPTIONS:
1. Governments can refuse to issue a patent for an invention if its
commercial exploitation is prohibited for reasons of public order or
morality. They can also exclude diagnostic, therapeutic and surgical
methods, plants and animals (other than microorganisms), and
biological processes for the production of plants or animals (other
than microbiological processes).Plant varieties, however, must be
protectable by patents or by a special system.
2. A patent owner could abuse his rights, for example by failing to
supply the product on the market. To deal with that possibility, the
agreement says governments can issue “compulsory licences”,
allowing a competitor to produce the product or use the process under
licence. But this can only be done under certain conditions aimed at
safeguarding the legitimate interests of the patent-holder.
ISSUES
An issue that has arisen recently is how to ensure patent protection for
pharmaceutical products does not prevent people in poor countries from
having access to medicines — while at the same time maintaining the patent
system’s role in providing incentives for research and development into new
medicines. Flexibilities such as compulsory licensing are written into the
TRIPS Agreement, but some governments were unsure of how these would
be interpreted, and how far their right to use them would be respected.
pg. 11
ability to use the flexibilities that are built into the TRIPS Agreement. And
they agreed to extend exemptions on pharmaceutical patent protection for
least-developed countries until 2016. On one remaining question, they
assigned further work to the TRIPS Council — to sort out how to provide
extra flexibility, so that countries unable to produce pharmaceuticals
domestically can import patented drugs made under compulsory licensing. A
waiver providing this flexibility was agreed on 30 August 2003.
pg. 12
IMPACT OF TRIPs ON India
pg. 13
4 Impact on electronic commerce It is important that each country have in
place a framework of intellectual property laws and regulations, and a
supporting infrastructure of intellectual property services, to reassure
intellectual property owners and commercial enterprises that their assets will
be protected in an online environment. Existence of such a legal
infrastructure offers three distinct advantages:
INDIA HAS INDIAN PATENT LAW 1970. It did not provided product
patents for pharmaceuticals, instead it provided production processes that
may be patented for seven years. In addition, the law allowed for
compulsory licences granted by the state, in the case of a patent holder's not
granting voluntary licences on fair conditions. India profited from a large
section of well-qualified experts who made good use of the new
opportunities.
pg. 14
Indonesia - and costs five to six times more in the USA and Great Britain.
But with new patent laws such benefits will not be available to Indian firms
and hence will lead to high increase in prices of such drugs.
pg. 15
the specific uses of a "biological agent (novel or pre-existing)"; and
the processes of gene technology.
• IPRs have helped to create a climate in biotechnology where only the
huge agricultural conglomerates can afford the costs of research and
patenting. By requiring developing countries to institute a strict IPR
regime, TRIPs creates an environment that will allow TNCs(Trans
national corporations) to dominate the agricultural industry.
• One of the direct costs of the 'biopatents' is that they can decrease the
independence of farmers. Prompted to keep up with the production of
high yield varieties, farmers that buy genetically modified organisms
(GMOs) for production are then locked into a relationship of
dependence with the patent owner-supplier. They are not legally
entitled to save and use seed, or keep the offspring from their
livestock without paying royalties to the patent owner. This pattern of
production moves farmers further away from sustainable farming
practices and increases their vulnerability to the vagaries of the
market.
• Indian farmers have used neem for generations as a pesticide and
fungicide. There are now more than 35 patents from the neem tree in
the United States and Europe. None of the profits from the patents are
returning to the traditional owners and the increased market cost has
resulted in decreased availability to local communities. Another
example was a patent granted in 1995 to US scientists for the use of
turmeric for healing wounds. They claimed its use to be novel
whereas this had been a traditional use, amongst others, in India for
centuries.
pg. 16
Traditional knowledge (TK) associated with biological resources is an
intangible component of the resource itself. TK has the potential of being
translated into commercial benefits by providing leads for development of
useful products and processes. The valuable leads provided by TK save time,
money and investment of modern biotech industry into any research and
product development. Hence, a share of benefits must accrue to creators and
holders of TK. Only new knowledge can be patented. Patents only apply to
inventions, not to existing knowledge. But if knowledge is held only in oral
form, then many IPR regimes, do not consider oral knowledge as proof of
previous documentation and therefore such knowledge is in danger of being
patented.
India is pressing for changes in the WTO TRIPs regime in order to protect
traditional knowledge and prevent bio-piracy. Issue was important for
developing countries as piracy of biological material and misappropriation
of traditional knowledge was taking place. Hence, India, along with some
other mega-biodiverse developing countries, is demanding a legally binding
regime which would enjoin all WTO members to amend their IPR laws.
REASONS:
Given the WTO patent regime, any lack of international public law measures
to protect against the usurpation of traditional knowledge may even result in
a situation where the traditional knowledge holders are deprived of rights to
use products which have been theirs for generations together. This is
pg. 17
extremely important, as the market value of plant-based medicines sold in
the OECD alone has been estimated at about $ 40-60 billion annually.
NEGOTIATIONS
It was noted that some developed countries were agreeable to the disclosure
of source and origin of country so long as it had no legal consequences on
the patent system. It was felt that this would not suffice
NORWEGIAN PROPOSAL
GI Extension Issues
pg. 18
Conclusion
Enforcement
India has one of the toughest copyright laws in the world. As is the case in
many other issues, enforcement holds the key to the problem. There are
several steps taken by various organisations (such as NASSCOM, etc) in
order to effectively implement these laws. The legislation has also been
modified to accommodate the hanging requirements posed by new
technological areas.
pg. 19
Recent disputes
1. With India accepting to comply with the norms of TRIPS on
pharmaceutical industry , there was a flood of patent applications filed
by several big pharmaceutical companies, which also included a
patent application by Novartis on Glivec in 1998.
Imatinib was an original invention by Novartis and glivec was seen as
an incremental innovation. The case included complicated matters like
whether Indian patent laws were upto the standard of TRIPS. Novartis
finally lost the case
2. Another famous case was filed by Roche to stop companies like Cipla
and Natco from manufacturing and selling a patented cancer vaccine
drug.
3. India has won a decade long battle against the granting of a patent to a
Neem - based crop fungicide by the European patent office (EPO).
India’s case was presented before EPO by Prof. U.P.Singh. Neem
derivatives have been traditionally used to make insect repellents,
soaps, contraceptives & Ayurvedic medicines & under normal
circumstances a patent application should always be rejected if there
is prior existing knowledge about the product
pg. 20
CRITICISMS
1. It provides a temporary monopoly where none else is allowed the free
flow of ideas or intellectual property
2. It may lead to private censorship where person holding right may
avoid the reproduction of idea
3. The global harmonization of IP laws are criticized by alter
globalization movements too who see it as an extension of US
influence on third world countries.
4. IP is basically of non rivalrous in nature because the person using it
does not devoid its original producer any access to it
5. Transaction losses are high while conferring such rights
6. Last it increases dead weight loss to the economy as one who has info
on latest technology to b used for production may curb its use and
may lead to rentenig process thus adding losses.
pg. 21
Bibliography
Websites:
www.wto.org
www.hg.org/intell/
www.ecommerce.ipo.int/
www.worldlegalforum.co.uk/
www.xime.com/
www.apnic.net/
www.indiainfoline.com
pg. 22